NRSN Valuation

Neurosense Therapeutics Ltd

Add to Watchlist

Advanced Chart

1.210

+0.03(2.542%)1D

Overview
Forecast
Valuation
Earnings

NRSN Relative Valuation

NRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRSN is overvalued; if below, it's undervalued.

Historical Valuation

Neurosense Therapeutics Ltd (NRSN) is now in the Fair zone, suggesting that its current forward PS ratio of 109.41 is considered Fairly compared with the five-year average of -1.99. The fair price of Neurosense Therapeutics Ltd (NRSN) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.21

Fair

-3.78

Trailing

Forward

0.00

EV/EBITDA

Neurosense Therapeutics Ltd. (NRSN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.98

EV/EBIT

Neurosense Therapeutics Ltd. (NRSN) has a current EV/EBIT of -2.98. The 5-year average EV/EBIT is -1.43. The thresholds are as follows: Strongly Undervalued below -3.50, Undervalued between -3.50 and -2.47, Fairly Valued between -0.40 and -2.47, Overvalued between -0.40 and 0.64, and Strongly Overvalued above 0.64. The current Forward EV/EBIT of -2.98 falls within the Undervalued range.

109.41

Neurosense Therapeutics Ltd. (NRSN) has a current PS of 109.41. The 5-year average PS is 6.67. The thresholds are as follows: Strongly Undervalued below -52.55, Undervalued between -52.55 and -22.94, Fairly Valued between 36.28 and -22.94, Overvalued between 36.28 and 65.89, and Strongly Overvalued above 65.89. The current Forward PS of 109.41 falls within the Strongly Overvalued range.

-2.90

P/OCF

Neurosense Therapeutics Ltd. (NRSN) has a current P/OCF of -2.90. The 5-year average P/OCF is -0.88. The thresholds are as follows: Strongly Undervalued below -3.27, Undervalued between -3.27 and -2.08, Fairly Valued between 0.31 and -2.08, Overvalued between 0.31 and 1.50, and Strongly Overvalued above 1.50. The current Forward P/OCF of -2.90 falls within the Undervalued range.

-2.90

P/FCF

Neurosense Therapeutics Ltd. (NRSN) has a current P/FCF of -2.90. The 5-year average P/FCF is -1.02. The thresholds are as follows: Strongly Undervalued below -3.91, Undervalued between -3.91 and -2.47, Fairly Valued between 0.42 and -2.47, Overvalued between 0.42 and 1.87, and Strongly Overvalued above 1.87. The current Forward P/FCF of -2.90 falls within the Undervalued range.

Neurosense Therapeutics Ltd (NRSN) has a current Price-to-Book (P/B) ratio of -55.94. Compared to its 3-year average P/B ratio of -9.62 , the current P/B ratio is approximately 481.36% higher. Relative to its 5-year average P/B ratio of -7.18, the current P/B ratio is about 678.91% higher. Neurosense Therapeutics Ltd (NRSN) has a Forward Free Cash Flow (FCF) yield of approximately -28.63%. Compared to its 3-year average FCF yield of -24.99%, the current FCF yield is approximately 14.58% lower. Relative to its 5-year average FCF yield of -21.60% , the current FCF yield is about 32.55% lower.

-55.94

P/B

Median3y

-9.62

Median5y

-7.18

-28.63

FCF Yield

Median3y

-24.99

Median5y

-21.60

Competitors Valuation Multiple

The average P/S ratio for NRSN's competitors is 23.14, providing a benchmark for relative valuation. Neurosense Therapeutics Ltd Corp (NRSN) exhibits a P/S ratio of 109.41, which is 372.82% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NRSN.O

Neurosense Therapeutics Ltd

Reviva Pharmaceuticals Holdings Inc

Loss

28.64M

ITRM.O

Iterum Therapeutics PLC

2.71

30.03M

NEUP.O

Neuphoria Therapeutics Inc

Loss

17.97M

CUPR.O

Cuprina Holdings (Cayman) Ltd

Performance Decomposition

Market capitalization of NRSN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NRSN in the past 1 year is driven by Unknown.